Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens Claassen

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptomsJens Claassen, Rainer Spiegel, Roger Kalla, et al.
Annals of the New York Academy of Sciences|July 23, 2016
Resting in darkness improves downbeat nystagmus: evidence from an observational studyRainer Spiegel, Jens Claassen, Julian Teufel, et al.
Neurology|December 1, 2022
Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 GangliosidosesKyriakos Martakis, Jens Claassen, Jordi Gascon-Bayari, et al.
Journal of Neurology|August 13, 2021
Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type CTatiana Bremova-Ertl, Jens Claassen, Tomas Foltan, et al.
Ebiomedicine|March 20, 2024
GAA-FGF14 disease: defining its frequency, molecular basis, and 4-aminopyridine response in a large downbeat nystagmus cohortDavid Pellerin, Felix Heindl, Carlo Wilke, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Intronic <i>FGF14</i> GAA repeat expansions are a common cause of downbeat nystagmus syndromes: frequency, phenotypic profile, and 4-aminopyridine treatment responseDavid Pellerin, Felix Heindl, Carlo Wilke, et al.
BMC Neurology|January 11, 2017
Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trialKatharina Feil, Christine Adrion, Julian Teufel, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Neurology, Neurosurgery, and Psychiatry|July 2, 2013
A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptomsJens Claassen, Rainer Spiegel, Roger Kalla, et al.
Annals of the New York Academy of Sciences|July 23, 2016
Resting in darkness improves downbeat nystagmus: evidence from an observational studyRainer Spiegel, Jens Claassen, Julian Teufel, et al.
Neurology|December 1, 2022
Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 GangliosidosesKyriakos Martakis, Jens Claassen, Jordi Gascon-Bayari, et al.
Journal of Neurology|August 13, 2021
Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type CTatiana Bremova-Ertl, Jens Claassen, Tomas Foltan, et al.
Ebiomedicine|March 20, 2024
GAA-FGF14 disease: defining its frequency, molecular basis, and 4-aminopyridine response in a large downbeat nystagmus cohortDavid Pellerin, Felix Heindl, Carlo Wilke, et al.
Medrxiv : the Preprint Server for Health Sciences|August 14, 2023
Intronic <i>FGF14</i> GAA repeat expansions are a common cause of downbeat nystagmus syndromes: frequency, phenotypic profile, and 4-aminopyridine treatment responseDavid Pellerin, Felix Heindl, Carlo Wilke, et al.
BMC Neurology|January 11, 2017
Effects of acetyl-DL-leucine on cerebellar ataxia (ALCAT trial): study protocol for a multicenter, multinational, randomized, double-blind, placebo-controlled, crossover phase III trialKatharina Feil, Christine Adrion, Julian Teufel, et al.
Pageof 2